Lynavoy: which tox species, and why?

“Linerixibat has been evaluated in oral repeat-dose general toxicity studies of up to 4, 26, and 39 weeks in mice, rats, and dogs, respectively.”

“The consistent absorption, distribution, metabolism, and excretion profile across rats, dogs, and humans supports the use of these nonclinical species for toxicological evaluation and provides confidence in the safety assessment for human use.”

“Linerixibat has been evaluated in oral repeat-dose general toxicity studies of up to 4, 26, and 39 weeks in mice, rats, and dogs, respectively.”